isotretinoin and Thoracic-Neoplasms

Patients <12 months with favorable biology, metastatic neuroblastoma have >90% overall survival following treatment with chemotherapy and surgery. We report two infants with favorable biology, stage 4 neuroblastoma with refractory disease after standard intermediate-risk chemotherapy and additional retrieval chemotherapy. One patient was treated with six additional cycles of isotretinoin and the other observed. Both remain clinically well with persistent disease but no evidence of tumor progression for 28 and 13 months following completion of cytotoxic treatment. Similar to residual tumor in primary sites, refractory metastatic disease may not portend a poor outcome in patients with favorable biology, intermediate-risk neuroblastoma.

Topics: Abdominal Neoplasms; Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Female; Humans; Infant; Isotretinoin; Lymphatic Metastasis; Male; Neuroblastoma; Orbital Neoplasms; Prognosis; Retroperitoneal Neoplasms; Risk; Salvage Therapy; Thoracic Neoplasms; Treatment Outcome; Watchful Waiting